#United States #New York #Securities Fraud #Rosen Law Firm #ADMA Biologics

Rosen Law Firm Investigates ADMA Biologics

The Rosen Law Firm, known worldwide for protecting investor rights, has launched a significant investigation into possible securities claims for shareholders of ADMA Biologics, Inc. (NASDAQ: ADMA). This action stems from serious allegations that the company may have disseminated misleading business information, impacting investor trust and financial standing.

Background of the Investigation

On March 24, 2026, an article by Investing.com reported that ADMA Biologics' stock experienced a notable decline of 16.6% in response to allegations made by Culper Research, a prominent short seller. The report alleged that ADMA engaged in channel stuffing to artificially inflate its revenue growth figures. This alarming accusation not only raises questions about the company's business practices but also the integrity of the information circulated among its investors.

The ramifications of such allegations are extensive, impacting not only stock prices but also shareholder trust. As a result, the Rosen Law Firm is taking proactive steps to protect the rights and interests of investors who may have been adversely affected by these developments.

How Investors Can Get Involved

Investors who purchased ADMA Biologics securities and feel that they might be entitled to compensation can do so without incurring any out-of-pocket expenses, thanks to a contingency fee arrangement proposed by the Rosen Law Firm. The firm is currently preparing a class action lawsuit aimed at recovering losses sustained by investors during this tumultuous period.

To register for this potential class action, investors can visit the Rosen Law Firm's dedicated webpage or contact Phillip Kim, Esq. directly via phone or email. The intent is to gather concerned shareholders and provide them with the necessary guidance and support in pursuing their claims.

The Rosen Law Firm's Expertise

The Rosen Law Firm has a commendable reputation in handling securities class actions and shareholder derivative litigation. Their successful history includes securing the largest class action settlement against a Chinese company, backed by recognition from ISS Securities Class Action Services as the top firm for securities class action settlements from 2013 to 2017.

Founding partner Laurence Rosen’s accolades, including being named a Titan of Plaintiffs' Bar by Law360, reflect the firm's commitment and effectiveness in advocating for investors. Their track record includes recovering hundreds of millions for their clients, positioning them as a formidable player in this niche legal arena.

Conclusion

As the investigation unfolds, it is crucial for investors in ADMA Biologics to stay informed and proactive. The Rosen Law Firm encourages affected shareholders to consider their options and to select competent legal counsel in light of the potentially fraudulent environment surrounding ADMA’s business disclosures. Shareholders can follow updates and further communication via the firm's social media platforms for ongoing information regarding the investigation and potential legal proceedings that may benefit them.

For those interested in the intricacies of securities law or who have invested in ADMA Biologics, the situation remains fluid, and timely action could prove beneficial. Whether or not this leads to a robust recovery of losses will depend on the collaborative efforts of the firm and the shareholders affected by these events.